01 / DESIGN
What was studied?
Seventy-three patients with hepatitis-B-related acute-on-chronic liver failure received standard care with or without thymosin alpha 1.
02 / FINDINGS
What did the researchers report?
The study reported higher transplant-free survival alongside changes in regulatory T-cell subsets and the time course of inflammatory markers.
03 / LIMITS
How should it be interpreted?
The trial was small and open-label in a severe, specific condition. Immune correlations do not prove which pathway produced the outcome, and broader claims require replication.
Voltera Peptide editorial reading note. Based on the linked source record. Methods and corrections.